Mode
Text Size
Log in / Sign up

Meta-analysis of salidroside in diabetic nephropathy animal models shows mixed renal outcomes with high heterogeneitySalidroside May Help Protect Kidneys in Diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note high heterogeneity in preclinical salidroside meta-analysis; clinical relevance unconfirmed.

This systematic review and meta-analysis synthesized evidence from preclinical studies involving 257 animals with diabetic nephropathy. The analysis focused on salidroside monotherapy compared with controls, examining renal function, blood glucose levels, serum creatinine, blood urea nitrogen, kidney index, antioxidant capacity, inflammatory mediators, and TGF-β1. Follow-up duration was not reported.

Pooled estimates demonstrated that salidroside-treated groups had lower serum creatinine (Hedges' g = −3.83; 95% CI −5.34 to −2.31) and lower blood urea nitrogen (Hedges' g = −2.90; 95% CI −4.50 to −1.30) than controls. Additionally, the kidney index was lower in treated groups (Hedges' g = −2.68; 95% CI −4.71 to −0.65). However, the pooled estimate for TGF-β1 did not reach statistical significance, although sensitivity analyses suggested the direction may favor salidroside.

The authors noted high heterogeneity and possible small-study or publication effects as key limitations. Anti-fibrotic effects, particularly regarding TGF-β1, remain sensitive to methodology. As this is preclinical evidence only, causality versus association is not explicitly distinguished, and safety data such as adverse events were not reported.

The Hidden Kidney Shield

Imagine living with diabetes and worrying about your kidneys slowly failing. You try everything, but the damage keeps creeping forward. Now, scientists have found a natural compound that might slow this down.

Diabetes is a common condition that hurts millions of people worldwide. High blood sugar over time can damage the tiny filters in your kidneys. These filters clean your blood, but when they get hurt, waste builds up.

Current treatments manage blood sugar well, but they do not always stop kidney damage. Many patients still face kidney failure despite taking their medicine. We need new ways to protect these vital organs.

The Surprising Shift

For years, doctors focused only on lowering blood sugar. We thought that was enough to save the kidneys. But here is the twist: lowering sugar alone does not fix all the damage.

New research suggests a different approach. A compound called salidroside, found in a plant called Rhodiola, might help. It works by calming inflammation and fighting oxidative stress in the body.

What Is Oxidative Stress?

Think of your cells like a car engine. When you drive too hard, the engine gets hot and parts rust. This is oxidative stress. In diabetes, high sugar creates extra heat and rust inside your cells.

Salidroside acts like a coolant and a rust remover. It helps clear out the harmful free radicals that attack your kidney cells. This keeps the tissue healthy and functioning better.

The Study Snapshot

Researchers looked at many past studies to get a clear picture. They searched databases from the beginning of time up to late 2025. They only included studies using animals with diabetes.

They found 14 studies involving 257 animals. The animals received salidroside as their only treatment for the kidney issue. This focused approach helped them see the direct effects of the compound.

The results were promising for kidney health. Animals taking salidroside had lower levels of creatinine in their blood. This is a key marker for kidney failure. Their blood urea nitrogen levels also dropped significantly.

These numbers mean the kidneys were working much better. The compound also helped lower blood sugar levels. It boosted the body's natural ability to fight damage.

But there is a catch.

The data was not perfectly consistent across all studies. Some results varied a lot from one experiment to another. Scientists call this heterogeneity. It means we cannot be 100% sure yet.

This is still in the research phase. Salidroside is not a new medicine you can buy at a pharmacy today. It is a natural substance found in plants.

You should talk to your doctor before trying any new supplements. Your doctor knows your specific health history. They can tell you if this is safe for you.

More research is needed to confirm these findings in humans. Scientists must run large, strict trials with people, not just animals. Only then can doctors recommend this as a standard treatment.

Until then, this study gives hope. It shows that nature might hold the key to saving our kidneys. We just need to prove it works safely in people.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundSalidroside (SAL), a principal bioactive constituent of Rhodiola species, has demonstrated renoprotective potential in diabetic nephropathy (DN). However, the magnitude of SAL’s effects on renal functional outcomes and key mechanistic biomarkers remains unclear.MethodsThis study was conducted in accordance with PRISMA 2020 guidelines. A comprehensive search was performed in PubMed, Embase, Web of Science, the Cochrane Library, and major Chinese databases from inception to 24 November 2025. Preclinical studies evaluating SAL monotherapy in DN animal models were included. Risk of bias was assessed using the SYRCLE tool and summarized in Review Manager (RevMan) 5.4. Meta-analysis was performed using Stata 18.0.ResultsFourteen studies (257 animals) were included. Pooled estimates suggested SAL was associated with improved renal function and lower blood glucose levels, despite substantial heterogeneity. Specifically, SAL-treated groups exhibited lower serum creatinine (Hedges’ g = −3.83, 95% CI -5.34 to −2.31), blood urea nitrogen (Hedges’ g = −2.90, 95% CI -4.50 to −1.30), and kidney index (Hedges’ g = −2.68, 95% CI -4.71 to −0.65) than controls. SAL also enhanced antioxidant capacity and suppressed inflammatory mediators. For TGF-β1, the pooled estimate did not reach statistical significance and showed heterogeneity, while sensitivity analyses suggested the direction of effect may favor SAL.ConclusionSAL provides preliminary preclinical evidence of renoprotection in DN models, potentially by modulating oxidative stress and inflammation. However, interpretation is constrained by high heterogeneity and possible small-study or publication effects. Anti-fibrotic effects, particularly TGF-β1, remain sensitive to methodology, necessitating caution. Rigorous, pre-registered animal trials are required to strengthen the evidence base.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251239960, identifier CRD420251239960.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.